Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Holden Comprehensive Cancer Center
Information provided by (Responsible Party):
John M. Buatti, University of Iowa
ClinicalTrials.gov Identifier:
NCT01065844
First received: February 8, 2010
Last updated: October 25, 2016
Last verified: October 2016
Results First Received: October 25, 2016  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Carcinoma, Adenoid Cystic
Head and Neck Neoplasms
Intervention: Drug: Nelfinavir

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Nelfinavir

1250 mg Nelfinavir twice daily Monday-Sunday

Nelfinavir: 1250 mg Nelfinavir twice daily Monday - Sunday


Participant Flow:   Overall Study
    Nelfinavir
STARTED   15 
COMPLETED   10 
NOT COMPLETED   5 
Adverse Event                5 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Nelfinavir

1250 mg Nelfinavir twice daily Monday-Sunday

Nelfinavir: 1250 mg Nelfinavir twice daily Monday - Sunday


Baseline Measures
   Nelfinavir 
Overall Participants Analyzed 
[Units: Participants]
 15 
Age, Customized [1] 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      12  80.0% 
>=65 years      3  20.0% 
[1] Age, in years, of study participants at consent
Gender, Customized [1] 
[Units: Participants]
Count of Participants
 
Female      9  60.0% 
Male      6  40.0% 
[1] Self-reported gender at time of study enrollment
Region of Enrollment 
[Units: Participants]
 
United States   15 


  Outcome Measures

1.  Primary:   Tumor Progression   [ Time Frame: Every 1 to 3 months ]

2.  Secondary:   Quality of Life   [ Time Frame: every 1 to 3 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Favorable selection criteria were used in study design. RECIST assessed at a median interval of 12 weeks - this difference in methods may have artificially prolonged the progression free survival observed in this study.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: John M. Buatti, M.D., Chair, Department of Radiation Oncology
Organization: The University of Iowa
phone: 319-356-2699
e-mail: john-buatti@uiowa.edu


Publications of Results:
Other Publications:

Responsible Party: John M. Buatti, University of Iowa
ClinicalTrials.gov Identifier: NCT01065844     History of Changes
Other Study ID Numbers: 200905704
Study First Received: February 8, 2010
Results First Received: October 25, 2016
Last Updated: October 25, 2016